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1. Introduction 
The term gastrointestinal stromal tumor (GIST) in the description of a specific group of 
gastrointestinal nonepithelial tumors lacking the microscopic evidence of smooth muscle or 
characteristics of neural immunoreactivity was first introduced by Mazur and Clark (Mazur 
& Clark, 1983). The common origin of GIST and interstitial cell of Cajal (ICC), the pacemaker 
cells in the digestive tract, was proposed due to their immunohistochemical and 
ultrastructural similarities. The definition of GISTs as tumors originating from ICC was 
further confirmed according to the findings that both GIST and ICC express KIT and that 
most GISTs have gain-of-function mutations of KIT, the proto-oncogene that encodes a 145 
kDa transmembrane tyrosine kinase KIT receptor. Mutation of different exons of the KIT 
oncogene results in activation of the tyrosine kinase activity of KIT, leading to ligand-
independent kinase activity and uncontrolled cell proliferation as well as resistance to 
apoptosis (Demetri et al., 2002; Hirota et al., 1998; Kindblom et al., 1998; Savage & Antman, 
2002). More than 90% of GIST have constitutive activation of the KIT protein as a result of 
KIT mutation and in GIST without KIT mutations, gain-of-function of platelet derived 
growth factor receptor α (PDGFRA) are present in about one-third of cases. It was recently 
proposed that ETV1, one of the ETS family transcription factor, can be a lineage survival 
factor that cooperates with KIT in gastrointestinal stromal tumours. GIST arises from ICCs 
with high levels of endogenous ETV1 expression that, when coupled with an activating KIT 
mutation, drives an oncogenic ETS transcriptional program (Chi et al., 2010; Roberts & 
Eisenberg, 2002; Rubin et al., 2001). 
GIST was estimated to occur in about 14.5 cases per million and was the most common 
mesenchymal tumor of the gastrointestinal tract. The most common locations of GIST are 
the stomach (50-60%), small intestine (20-30%), colon and rectum (10%), and esophagus 
(5%). Patients mostly present with nonspecific symptoms and signs (69%) and initial 
metastasis was noted in about 15-50% of GISTs (DeMatteo et al., 2000; Fletcher et al., 2002; 
Nilsson et al., 2005; Roberts & Eisenberg, 2002; Shinomura et al., 2005). 
The accurate diagnosis of GIST should be based on tumor morphology and 
immunohistochemistry. GIST tumors grossly appear as well-defined submucosal lesion 
with prominent vasculature and occasional hemorrhage or ulceration (Fig. 1A and 1B.). 
Under morphologic examination in the immunohistochemical analysis, GIST tumor cells are 
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generally classified as three morphologic subtypes, including spindle cell type in the 
majority, epithelioid cell type and mixed type composed of both spindle and epithelioid 
cells (Fig. 1C). Similarly, tumor cells in GIST cell lines in vivo presents as spindle cell 
morphology in the majority, regardless of the types of the GIST cell line (Fig. 1D).  
 
 
Fig. 1. Macroscopic and microscopic inspection of GIST tumor. 
A. Small intestinal GIST. B. GIST tumor with central ulceration. C. GIST tumor cell by 
immunohistochemical staining demonstrating both types of spindle and epithelioid tumor 
cells. D. GIST tumor cell line. 
In the diagnosis of GIST, KIT has been shown to be a specific and sensitive marker in the 
differential diagnosis of gastrointestinal mesenchymal tumors. The majority of GISTs 
express KIT, and approximately only 4-5% of GISTs are KIT negative. There may be 
different KIT-staining patterns  KIT-negative GISTs preferentially occur in the stomach and 
usually show pure epithelioid or mixed cytomorphology (Debiec-Rychter M ei al., 2004; 
Hirota et al., 1998; Kindblom et al., 1998; Medeiros et al., 2004).  
In recent years, numerous antibodies for the diagnosis of GIST have been identified. These 
immunohistochemical markers were mainly noted and verified in molecular studies and 
may be of value in the diagnosis in KIT-negative GISTs. Discovered on GIST (DOG1), an up-
regulated transmembrane protein found in GISTs, is one of the markers of significance.  
Recent studies have demonstrated that antibodies against DOG1 have greater sensitivity 
and specificity than KIT (CD117) and CD34, serving as specific immunohistochemical 
markers for GIST regardless of the KIT/PDGFRA mutation or KIT immunohistochemical 
expression. Carbonic anhydrase II (CA II) and protein kinase C (PKC)-theta, a member of 
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the protein kinase C family, in addition to being biomarkers frequently expressed in the 
majority of GISTs with high specificity, are also of diagnostic as well as prognostic values 
(Blay et al., 2004; Duensing et al., 2004; Espinosa et al., 2008; Lee et al., 2008; Liegl et al., 2009; 
Miettinen et al., 2009; Parkkila et al., 2010; West, RB et al., 2004). 
The role of biopsy in the diagnosis of GIST is unclear. In tumors with fragile consistency and 
hypervascularity, biopsy is not suggested due to risk of bleeding, capsular perforation with 
rupture and tumor seeding. Although tissue biopsy can be conducted safely and accurately 
by endoscopy or other image-guided methods, the submucosal location of the tumors often 
make accurate sampling difficult. Necrosis, ulceration and hemorrhage are common in GIST 
tumor tissues and may limit and preclude the feasibility and plausibility of fine needle 
aspirates or core biopsies. In certain situations, biopsies may be of value in differential 
diagnosis when other disease entities are suspected or when diagnosis is necessary for 
subsequent planning of treatment (Garcia dePolavieja et al., 2010) 
Imaging studies play a diagnostic role for evaluation of suspected GIST patients for 
characterization of the tumor. Contrast-enhanced computerized tomography (CT) scanning 
and occasionally magnetic resonance imaging (MRI) are the imaging modality of choice for 
initial evaluation and [18F]2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-
PET)/CT has recently become important in both diagnosis and assessment of tumor 
response to targeted therapy in the adjuvant as well as neoadjuvant therapy in GIST. 
For small tumors found incidentally, CT scanning or endoscopic ultrasound is 
recommended (Blackstein et al., 2006; Van den Abbeele et al., 2008). 
While the treatment of GISTs with radiotherapy or systemic chemotherapy was 
unsuccessful in the majority, complete surgical resection remains the gold standard in the 
management of primary GIST. The recurrence rate of GIST, even in patients with resectable 
GIST, ranges from 17 to 24% in some series but chas also been reported to be as high as 80%. 
The median survival for patients with recurrence is about 9-12 months (Demetri et al., 2002; 
Iesalnieks et al., 2005; Nilsson et al., 2005 ; Shinomura et al., 2005; Zhu et al., 2010). 
Imatinib mesylate, an tyrosine kinase inhibitor (TKI) for both normal and mutated KIT 
found in most GISTs, was the first effective drug in the treatment of metastatic GIST and 
was approved by the Food and Drug Administration (FDA) for the treatment of 
unresectable and metastatic GIST in 2002 (Kwon et al., 2001; DeMatteo et al., 2002; Demetri 
et al., 2002; Savage & Antman, 2002). Adjuvant therapy with imatinib theoretically might 
improve the curative rate after complete resection of primary GIST by eradicating residual 
microscopic disease. Trials on adjuvant imatinib after complete resection of primary GIST 
have been evaluated in patients with a substantial risk of relapse. Recent studies confirmed 
that adjuvant target therapy with imatinib was effective in improving disease-free survival 
in GIST after surgery in high-risk patients  , potentiating upcoming wide clinical application 
of adjuvant imatinib treatment in GIST. Since the introduction of imatinib as the target 
therapy for treatment of advanced GIST, acquired or secondary resistance to imatinib was 
found to develop in some GIST patients (Corless et al., 2004; Dematteo et al., 2009; Demetri 
et al., 2002; Heinrich & Corless, 2005; Verweij et al., 2004). Another tyrosine kinase inhibitor, 
sunitinib malate has recently been approved as a second-line treatment for GIST patients 
who develop resistance to or cannot tolerate imatinib. Sunitinib has also been approved by 
the US FDA as second-line therapy for patients with advanced GIST. Newer agents are 
currently being evaluated in clinical trials. Identifying factors or biomarkers predicting high 
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risk of disease progression in GIST patients thus becomes increasingly important and has 
been reported in numerous studies (Blanke et al., 2009; Corless et al., 2004; Keun et al., 2008).  
Numerous studies have been devoted to the identification of specific clinical and 
pathological markers of prognostic significance (Hsu et al., 2007a, 2007b, 2010a, 2010b; 
Kwon et al., 2001; Miettinen et al., 2002; Rudolph et al., 1998 ; Yan et al., 2003). Among 
miscellaneous prognostic parameters, tumor size and mitotic figure have been considered 
most useful and reliable predictive variables for prognosis with good reproducibility and 
statistical consistency. A Consensus guidelines and classification system for GIST risk 
stratification, referred to as the National Institutes of Health (NIH) Consensus Criteria for 
GIST risk stratification, that categorizes GIST patients with GIST into low, intermediate, and 
high-risk groups according to these two parameters has been proposed and was widely 
applied in the clinical setting for risk analysis for patients with GIST (Hsu et al., 2007a, 
2007b;  Fletcher et al., Shinomura et al., 2005). 
Recently, the integration of tumor locationas the third parameter in NIH Consensus Criteria 
for GIST risk stratification, with intestinal localization of the tumor being a poor prognostic 
factor, was proposed to help more accurately predicting risk of recurrence and poor 
prognosis after surgery in patients with GIST, so that potential candidates for adjuvant 
imatinib therapy can be identified (Gold et al., 2009; Joensuu, 2008; Patel, 2011). 
With the advent and rapid progress in the development as well as application of TKI in 
GIST, the treatment of GIST evolves significantly in recent years. Adjuvant, neoadjuvant 
therapy and new TKI agents are among the most focused issues of intensive investigations 
in the management of GIST in the post-TKI era. Revolutionary innovations in surgical 
techniques such as newly developed laparoscopic modalities have also contributed to the 
armamentarium of GIST management. Treatment options for GIST with respect to disease 
stages and different intervention strategies will be presented in this chapter.  
2. Primary resectable GIST 
2.1 General principles of surgery 
Surgical resection has been the standard treatment for patients with localized, resectable 
GISTs. Specific surgical strategies are required according to the organ involved, tumor 
location, and tumor size. The goal of resection is to achieve complete (R0) excision of the 
tumor with negative margins, in the absence of residual disease grossly and microscopically. 
In general, primary GIST tumors tend not to invade surrounding organs or tissues. Wedge 
or segmental resection of the involved organs or tissues bearing the tumor is adequate. 
Lymph node metastasis is uncommon and lymphadenectomy has been considered 
unnecessary in GIST. In rare occasions when enlarged nodes are found at the time of 
operation, these should be removed with the primary GIST tumor. It is generally acceptable 
that a margin of 2 cm be adequate. However, there are no prospectively collected data 
available with regard to the adequate margin and to whether the extent of resection margins 
correlate with the risk of tumor recurrence or metastasis.  
During operation, care should be taken to thoroughly evaluate the peritoneal cavity, 
especially the liver and peritoneum, the most common sites of disease spread for metastasis. 
Suspicious peritoneal lesions should be resected. Extreme care should also be taken during 
manipulation of the tumor to prevent excessive bleeding and peritoneal dissemination of 
tumor cells so that tumor rupture, one of the contributing factors associated with recurrence, 
does not happen. 
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Before the TKI era, surgery was the only curative and effective treatment for GISTs. Recemt 
studies have proved that adjuvant imatinib can delay recurrence and improve survival in 
selected patients with high-risk GIST. In patients with advanced or metastatic GIST, 
imatinib is the standard treatment, wiht surgery of residual masses being an option. 
Preoperative imatinib is an emerging and promising treatment of choice for patients with 
initially unresectable GIST. Such neoadjuvant therapy offers the chance of converting or 
reduction of the unresectable GIST into resectable diseases. 
2.2 Surgery in relation to tumor location 
2.2.1 Gastric GIST 
The stomach is the most common tumor location for GISTs. Patients often present with GI 
bleeding or obstruction. Their diagnosis and are usually made by endoscopy and 
endoscopic ultrasound that identifies the intramural origin of the tumor. Biopsy 
occasionally may of help in the diagnosis of GIST. Small tumors are occasionally found 
during endoscopy for other indications and endoscopic resection when feasible may be 
indicated. Surgical intervention is necessary for gastric GIST not amenable to endoscopic 
resection and depends primarily on the location and size of the tumor within the stomach. 
As with all GISTs, the principle operative treatment is complete resection with negative 
margins. Special care should be taken to prevent potential tumor rupture by meticulously 
manipulating the tumor during the operation. The location of GIST in the lower third of the 
stomach may be a favorable factor, however, the exact significance of different tumor sites 
for prognosis of gastric GISTs needs to be further clarified. Most would advocate a distal 
gastrectomy with Billroth I or II reconstruction in tumor of considerable sizes. Proximal 
lesions on the lesser curve orlocalization close to the gastroesophageal junction may be 
difficult to surgical resection, especially in tumors with large-sized or wide base. In tumors 
that become adherent to adjacent structures, en bloc excision with omentectomy, 
splenectomy, or distal pancreatectomy may be indicated to ensure capsule integrity as well 
as R0 resection. Unlike gastric cancer, omentectomy or lymphadenectomy is not necessary 
unless the presence of involvement by intraoperative evaluation (Gervaz et al., 2009; Huang 
et al., 2010; Miettinen et al., 2005; Privette et al., 2008; Silberhumer et al., 2009). 
2.2.2 Small intestinal GIST 
The incidence of GIST originating from the small intestine is secondary to that of gastric 
GIST. Small intestinal GIST of duodenal origin is rare with the incidence of less than 5%. 
While a majority of patients present with bleeding, large tumors can lead to GI obstruction. 
The best modality for diagnosis of duodenal GIST is endoscopy. Similar to gastric GIST, the 
operation depends on the size and location of the primary tumor as well as distance from 
the ampulla. One recent study showed that type of operation was not correlated to operative 
risk and disease recurrence, limited operation rather than more radical 
pancreaticoduodenectomy should be attempted whenever possible for duodenal GIST 
without involvement of papilla of Vater to preserve more pancreas parenchyma, 
duodenum, and common bile duct (Chung et al., 2010; Miettinen et al., 2003; Yang et al., 
2009). 
Intestinal GIST other than duodenal origin can be difficult to diagnose. CT or capsule 
endoscopy are optional tools in diagnosis. In this disease entity, there is a higher proportion 
of lesions found in the jejunum than the ileum. The same surgical principles of negative 
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margins and prevention of tumor rupture apply equally to intestinal GISTs, regardless of 
the tumor location. This is best accomplished by segmental small bowel resection with 
primary anastomosis. As mentioned earlier, intestinal location was an independent 
predictor of recurrence and poor prognosis (Dematteo et al., 2008; Miettinen et al., 2005, 
2006).  
2.2.3 Colorectal GIST 
Reports regarding GIST of colon and rectal origin have been limited in number due to its 
rarity. Surgical consideration of these colorectal GISTs is the same as that mention in GIST of 
other locations and may include local exicision or radical resection. However, for rectal 
GISTs, its rarity makes it difficult to assess the role of the extension of the surgical resection 
of the tumor. Colonic GISTs are typically treated with segmental resection and primary 
anastomosis. Unlike colon cancer, formal lymphadenectomy is not necessary unless obvious 
nodal involvement is present. Resection of rectal GISTs is more difficult and is often 
associated with increased rate of complication. A formal mesorectal excision is unnecessary 
and often leads to increased morbidity. One study retrospectively analyzed clinical 
characteristics of surgically treated gastrointestinal stromal tumors of the colon and rectum 
and demonstrates that the majority of colorectal GISTs are high-risk. Patients with high-risk 
colorectal GISTs have a significant likelihood of developing metastases that is associated 
with poor prognosis. These patients need to be closely followed for an extended period and 
should be considered for adjuvant therapy with tyrosine kinase inhibitors. Since rectal 
GISTs are often advanced, the role of neoadjuvant Imatinib in rectal GIST has also been 
evaluated. It has been proposed that preoperative Imatinib therapy can contribute to 
reduction of the size in large rectal GISTs, improving the chances of successful radical 
surgery and therefore decreasing the risk of morbidity and mortality (Hassan et al., 2006; 
Hou et al., 2009; Machlenkin et al., 2010; Mandalà et al., 2007).  
2.3 Endoscopic resection 
Small GIST lesions are often found incidentally during endoscopy or laparotomy for specific 
indications. The diagnosis of GIST is often made after endoscopic ultrasound (EUS) referral 
for the evaluation of submucosal lesions. Its diagnostic yield can vary. It can be as low as 
68.7% without tissue acquisition and as high as 84% with tissue acquisition (Scarpa et al., 
2008). When GISTs are accidentally found during routine endoscopy, decision-making may 
be difficult because of the lack of data regarding biology behavior, invasiveness and 
metastatic potential of these tumors. Endoscopic features are unable to predict tumor 
behavior reliably. Once a diagnosis of GIST is confirmed and metastatic disease excluded, 
subsequent surgical intervention should take into consideration the size and location of the 
tumor. Treatment of small lesions incidentally found during endoscopy, imaging studies, or 
surgical exploration for other indications remains controversial. It is agreed that small 
tumors identified at the time of laparotomy or laparoscopy be removed whenever possible 
without increasing the risk of tumor rupture or risk of complication such as perforation or 
hemorrhage. A reasonable strategy can include close follow-up and surveillance in 6–12 
months. For lesions more than 2 cm in size, surgical resection is the principle treatment and 
is the only curative treatment of choice. Endoscopic ligation and resection shows promise as 
a safe and feasible technique to treat small EUS-suspected gastric GISTs (Casali et al., 2010). 
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2.4 Minimally invasive surgery  
The role of laparoscopic approaches in the surgical management of GIST has gained 
increasing popularity due to the technical advantage of complete resections in a minimally 
invasive manner. With appropriate handling of the tumor, laparoscopic surgery has been 
proved safe and effective in selected patients. Laparoscopy is particularly being used with 
increasing frequency for GIST originating from the stomach. Laparoscopic resection of 
gastric GISTs appears technically feasible and is associated with favorable outcomes. It is 
generally agreed that tumors up to 5 cm can be safely approached laparoscopically. It is also 
important to follow the same surgical principles of laparotomy when performing 
laparoscopic GIST resections, including complete R0 resection with free margins, avoidance 
of accidental tumor rupture intraoperatively, and use of a retrieval bag to prevent spillage 
and seeding of tumor cells into the peritoneum. While there has been no prospective 
randomized trial directly comparing laparoscopic and open approaches for gastric GIST, 
several retrospective series have demonstrated that the laparoscopic approach is associated 
with low morbidity, mortality, and satisfactory oncologic results. Laparoscopic surgery can 
be conducted in combination with intra-operative endoscopic assistances according to 
tumor size and location. Innovative techniques in laparoscopic surgery, including single-
port laparoscopic surgery or incisionless surgical approach such as natural orifice 
transluminal endoscopic surgery (NOTES), have been applied in clinical practice in recent 
years. These surgical approaches have been reported to be associated with significantly 
fewer complications, reduced pain, faster recovery, and improved cosmesis compared with 
traditional open or laparoscopic approaches. It is likely that these newly developed 
minimally invasive surgery will be applied to miscellaneous surgical diseases, including 
GIST, in the near future (Catena et al., 2008; Choi et al., 2007; Horgan et al., 2011; Karakousis 
et al., 2011; Kingham & DeMatteo, 2009; Novitsky et al., 2006; Otani et al., 2006; Privette et 
al., 2008; Sasaki et al., 2010; Sexton et al., 2008Woodall et al., 2009).  
2.5 Adjuvant therapy 
The success of IM in the treatment of metastatic GIST and the significant risk of recurrence 
of GIST in the pre-TKI era with surgery alone stimulated investigation of complete surgical 
resection in combination with TKI treatment as adjuvant intent. The efficacy of standard 
dose adjuvant imatinib mesylate (400 mg/day) has been evaluated in clinical trials. The 
American College of Surgeons Oncology Group (ACOSOG) sponsored two randomized, 
double-blind, placebo-controlled studies evaluating adjuvant imatinib in completely 
resected, localized primary GIST. Based on the positive results from these clinical trials, the 
US FDA approved 400 mg/day imatinib mesylate tablets for oral use for the adjuvant 
treatment of adult patients following complete gross resection of gastrointestinal stromal 
tumor (GIST) with tumors larger than 3 cm on December 19, 2008 (DeMatteo et al., 2009). 
Several studies reported similar outcomes demonstrating that imatinib used in the adjuvant 
therapy improved recurrence-free survival significantly (Essat & Cooper, 2011). The 
duration of adjuvant therapy remains controversial and was not specified in the Food and 
Drug Administration approval since the rate of recurrences in the imatinib mesylate treated 
group seemed to increase at 18 months from surgery which corresponded to 6 months after 
discontinuing the study drug. Similar times to progression were also noted after treatment 
interruptions in patients with metastatic disease.New trials for evaluation of optimal 
duration for adjuvant therapy are currently undergoing that includes two large European 
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trials aimed to clarify and evaluate the adjuvant duration: the Scandinavian Sarcoma Group 
(SSG) and the German Arbeitgemeinschaft Internistische Onkologie (AIO) are jointly 
conducting a randomized, phase III trial (SSGXVIII/AIO) to evaluate 1 year versus 3 years 
of adjuvant imatinib mesylate, inhigh-risk GIST patients. The European Organization for 
Research and Treatment of Cancer (EORTC) 62024 study compares adjuvant therapy for 2 
years with observation (Blay et al., 2007).  
3. Recurrent GIST 
Surgery is the mainstay of treatment for primary resectable GISTs when there is no evidence 
of metastases or advanced diseases. Although surgery is the only known potentially 
curative treatment for primary resectable or marginally resectable GISTs, 40–90% of 
surgically treated patients experience disease recurrence despite complete surgical resection 
according to the literature. Five-year recurrence-free and disease-free survival rates of 49% 
and 65%, respectively, have been reported for patients undergoing complete resection. 
Prevention or identification of risk factors associated with increased rate of recurrence thus 
become one important issue in the surgical treatment of GIST (Hassan et al., 2008; Rossi et 
al., 2003; Singer et al., 2002). 
Although it is clear that rupture of GIST tumor at operation carries a high risk of tumor 
recurrence, appropriate surgical management options and the associated outcomes in 
patients with a ruptured GIST is not clarified. One recent report showed that the risk of 
recurrence approaches nearly 100% in patients with GIST that ruptured into the abdominal 
cavity before or during operation and the associated recurrence-free survival was less than 1 
year, emphasizing the necessity of adjuvant therapy in these group of high-risk patient. 
Another study investigates long-term follow-up of the imatinib mesylate treatment in 
patients with GIST would experience tumor recurrence or metastasis after radical resection 
and found that the imatinib mesylate treatment could prolong the survival of the patients 
who have recurrent GIST after the radical surgery (Zhu et al., 2010). 
4. Advanced/metastatic GIST and targeted therapy 
Initial metastasis can be present in about 15-50% of GIST patients (DeMatteo et al., 2000; 
Roberts & Eisenberg., 2002; Shinomura et al., 2005). Treatment guidelines for GIST all 
recognize imatinib as the standard of care for patients with advanced, unresectable, and 
metastatic GISTs. Imatinib mesylate has been proven to play a significant role in the 
treatment of advanced/metastatic GIST and has been considered the standard first line 
therapy in this patient group. Prognosis of patients with advanced disease improved 
significantly following the approval of imatinib mesylate in 2001 by FDA for this indication. 
The overall survival can be improved significantly in patients with advanced GIST. Patients 
who develop resistance to or are intolerant of first-line imatinib mesylate are commonly 
treated with sunitinib malate, a multi-targeted tyrosine kinase inhibitor approved by the 
FDA in January 2006 as second-line therapy in this disease (Blanke et al., 2008; Casali et al., 
2009; Demetri et al., 2000, 2002, 2006; Nishida et al., 2008). 
In the majority of patients with advanced, unresectable or metastatic GIST receiving 
imatinib treatment shows variable response. Response to treatment can be evaluated on CT 
scan as reduction of the tumor size or as decreased FDG uptake on a PET/CT scan. In the 
minority of cases, tumor progression develops within the first 6 months in spite of 
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treatment, refered to as primary resistance, and in a subset of patients, the tumor may 
remain unchanged despite treatment. Secondary resistance is defined as situations when 
patients with initially good response or stable disease develop tumor progression after 12-36 
months of treatment. Molecular mechanisms responsible for primary resistance differ from 
those of secondary resistance. KIT exon 9 and PDGFRA mutations more commonly are 
associated with primary imatinib resistance when compared to KIT exon 11 mutations. 
Secondary resistance is most commonly related to secondary mutations in the KIT kinase 
domain (Gajiwala et al., 2009; Heinrich et al., 2006, 2008; Liegl et al., 2008).  
The success and significant effects of imatinib mesylate and sunitinib malate in their clinical 
application have led to miscellaneous investigations on a wide variety of new TKI for their 
potential roles in the treatment of GIST, including Nilotinib, Sorafenib, Masitinib (AB1010), 
Vatalanib (PTK787/ZK 222584). The majority of these multi-targeted tyrosine kinase 
inhibitors are designed as novel or third-line agents for treatment in imatinib-resistant GIST 
or imatinib and sunitinib-resistant GIST. If proved of their efficacy against GIST in currently 
clinical trials, these novel TKI agents will bring about a new TKI era and will definitely hold 
promise for future targeted therapy in GISTs (Guo et al., 2007; Joensuu et al., 2011; Le Cesne 
et al., 2010; Prenen et al., 2006; Sawaki et al., 2011).  
5. Neoadjuvant therapy 
Neoadjuvant, or downsizing treatment, defined as surgical resection for patients with 
previously unresectable GISTs after treatment with imatinib or other TKI, is indicated for 
reduction of tumor volume and for eradicating potential microscopically metastatic tumor 
cells prior to surgery. The rationale for neoadjuvant imatinib is based on the elimination of 
microscopic and metastatic disease, with additional benefits of preoperative cytoreduction 
of tumors, facilitating complete resection and function-sparing surgical procedures, offering 
selected patients with initially unresectable diseases chances of resectability and operability. 
In addition, if a significant response of tumor to such neoadjuvant therapy can be achieved, 
the risk of tumor rupture during surgical manipulation, and thus the potential of post-
operative recurrence, can also be reduced theoretically. 
Neoadjuvant therapy should be individualized and is indicated for patients with large 
tumors where resection would cause undo morbidity or functional deficit, and small tumors 
in difficult to treat areas such as the gastroesophageal junction or low rectum. Retrospective 
reports and prospective investigations evaluating the efficacy of imatinib in the neoadjuvant 
therapy for GIST have demonstrated promising results in terms of cytoreduction and 
facilitating conservative, organ-preserving surgery, as well as survival and prognostic 
benefits (Abhyankar & Nair, 2008; Andtbacka et al.,2007; Blesius et al., 2011; DeMatteo et al., 
2007; Eisenberg et al., 2009; Fiore et al., 2009; Sjölund et al., 2010).  
As a general, neoadjuvant imatinib should be considered if surgery could result in 
significant morbidity or loss of organ function, and subsequent surgery may be considered 4 
to 12 months later after maximal tumor size reduction. Similar to adjuvant therapy, it 
remains relatively controversial as to the optimal duration of neoadjuvant therapy as well as 
the optimal timing of surgical intervention in this particular group of GIST patients. It is 
proposed that he timing of the surgical procedure can be critical in that resection should be 
conducted upon maximal response of the tumor to neoadjuvant imatinib before the 
development of tumor progression. The majority of patients with advanced GIST reach a 
response within 6 months of neoadjuvant therapy, with a median time to response of 3 
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months. In patients with GIST responding to neoadjuvant therapy, the time interval before 
potential resection should not be less than 3 months. Patients can be followed closely with 
serial CT scans to assess and document progressive reduction of the tumor size (Gold & 
DeMatteo, 2006, 2007).  
PET scan is of importance in the neoadjuvant therapy for GIST in its role as an early and 
sensitive imaging tool for evaluation of the response of GIST to neoadjuvant treatment in 
the clinically setting. PET scans can help document tumor activity if the biologic effect of 
imitinab is unclear clinically. Response of the tumor can be detected and determined by 
PET after a week or less of neoadjuvant treatment and precedes CT response by several 
weeks. This could be of great value in patients with unresectable and advanced GIST, for 
which timely and accurate assessment of tumor response to adjuvant treatment is 
imperative to subsequent surgical strategies (Bumming et al.,2003; Dimitrakopoulou-
Strauss et al., 2007; Katz et al., 2004; Lo et al., 2005; Loughrey et al., 2005; Raut & 
DeMatteo, 2008; Rutkowski et al., 2006; Shah et al., 2005; Stroobants et al., 2003; Yoon & 
Tanabe, 2007). 
It may be a matter of time when neoadjuvant therapy, like adjuvant therapy, becomes 
standard treatment of choice in selected GIST patients with advanced or initially 
unresectable diseases if the optimal duration of treatment in both adjuvant and neoadjuvant 
therapy can be documented and substantiated. 
6. Conclusion 
The management of human malignancies, including GIST, requires a multidisciplinary 
team approach. In primary resectable GIST, the standard treatment remains surgery, 
which takes into consideration tumor location and tumor size in preoperative 
assessment. Innovation and evolvement in surgical techniques in the treatment of GIST 
should always accompany the general surgical principle of complete resection with 
negative margin and meticulous manipulation of tumor without rupture. The success of 
targeted therapy with imatinib mesylate in the treatment of advanced/metastatic GIST 
has revolutionized the management of GIST: in addition to emerging clinical 
investigations evaluating the effects of novel tyrosine kinase inhibitors in GIST, the 
significant role of imatinib mesylate and other tyrosine kinase inhibitors in the adjuvant 
and neoadjuvant therapy in different GIST patient groups has been proved and 
substantiated. The importance of adjuvant as well as neoadjuvant therapy in the 
management of GIST will continue to be emphasized and verified. It is likely that future 
treatment in GIST will move toward individualized targeted therapy in combination 
with surgery in order to optimize clinical outcomes including improved survival, 
reduced risk of recurrence and better quality of life. 
7. References 
Siegwart, R. (2001). Indirect Manipulation of a Sphere on a Flat Disk Using Force 
Information. International Journal of Advanced Robotic Systems, Vol.6, No.4, 
(December 2009), pp. 12-16, ISSN 1729-8806 
Abhyankar, SA. (2008). Highlighting the role of FDG PET scan in early response assessment 
of gastrointestinal stromal tumor treated with imatinib mesylate. Clinical Nuclear 
Medicine, Vol.33, No.3, (March 2008), pp. 213-214, ISSN 0363-9762 
www.intechopen.com
 
Treatment Options for Gastrointestinal Stromal Tumors 
 
39 
Andtbacka, RH. (2007). Surgical resection of gastrointestinal stromal tumors after treatment 
with imatinib. Annals of Surgery Oncology, Vol.14, No.1, (January 2007), pp. 14–24, 
ISSN 1068-9265 
Blackstein, ME. (2006). Gastrointestinal stromal tumours: consensus statement on diagnosis 
and treatment. Canadian Journal of Gastroenterology, Vol20, No.3, (March 2006), 
pp.157-163, ISSN 0835-7900 
Blanke, CD (2009). Biomarkers in GIST: partly ready for prime-time use. Clinical Cancer 
Research, Vol.15, No.18, (September 2009), pp. 5603-5605, ISSN 1078-0432 
Blanke, CD. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at 
two dose levels in patients with unresectable or metastatic gastrointestinal stromal 
tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical 
Oncology, Vol.16, No.4, (February 2008), pp. 626-632, ISSN 0732-183X 
Blay, JY. (2007). Prospective multicentric randomized phase III study of imatinib in patients 
with advanced gastrointestinal stromal tumors comparing interruption versus 
continuation of treatment beyond 1 year: the French Sarcoma Group. Journal of 
Clinical Oncology, Vol.25, No.9, (March 2007), pp. 1107-1113, ISSN 0732-183X 
Blay, P. (2004). Protein kinase C theta is highly expressed in gastrointestinal stromal tumors 
but not in other mesenchymal neoplasias. Clinical Cancer Research, Vol.10, No12, 
(June 2004), pp. 4089–4095, ISSN 1078-0432 
Blesius, A. (2011). Neoadjuvant imatinib in patients with locally advanced non metastatic 
GIST in the prospective BFR14 trial. BMC cancer, Vol.15, No.11, (February 2011), pp. 
72, ISSN 1471-2407 
Bumming, P. (2003). Neoadjuvant, adjuvant and palliative treatment of gastrointestinal 
stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. British 
Journal of Cancer, Vol.89, No.3, (August 2003), pp. 460–464, ISSN 0007-0920 
Casali, PG. (2010). Gastrointestinal stromal tumours: ESMO clinical recommendations for 
diagnosis, treatment and follow-up. Annals of Oncology, Vol.21, Suppl.5, (May 2010), 
pp. 64–67, ISSN 0923-7534 
Catena, F. (2008). Laparoscopic treatment of gastric GIST: report of 21 cases and literature’s 
review. Journal of Gastrointestinal Surgery, Vol.12, No.3, (March 2008), pp. 561–568, 
ISSN 1091-255X 
Chi, P. (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal 
Choi, SM. (2007). Laparoscopic wedge resection for gastric GIST: long-term follow- up 
results. European Journal of Surgical Oncology, Vol.33, No.4, (May 2007), pp. 444–447, 
ISSN 0748-7983 
Chung, JC. (2010). Surgery for gastrointestinal stromal tumors of the duodenum. Annals of 
Surgical Oncology, Vol.14, No.5, (May 2010), pp. 880-883, ISSN 1091-255X 
Corless, CL. (2004). Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology, 
Vol.22, No.18, (September 2004) , pp. 3813-3825, ISSN 0732-183X 
Debiec-Rychter, M. (2004). Gastrointestinalstromal tumours (GISTs) negative for KIT 
(CD117 antigen) immunoreactivity. Journal of Pathology, Vol.202, No.4, (April 2004), 
pp. 430–438, ISSN 0022-3417 
DeMatteo, RP. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns 
and prognostic factors for survival. Annals of Surgery, Vol.231, No.1, (January 2000), 
pp. 51-58, ISSN 0003-4932 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
40
DeMatteo, RP. (2007). Results of tyrosine kinase inhibitor therapy followed by surgical 
resection for metastatic gastrointestinal stromal tumor. Annals of Surgery, Vol.245, 
No.3, (March 2007), pp. 347–352, ISSN 0003-4932 
Dematteo, RP. (2008). Tumor mitotic rate, size, and location independently predict 
recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 
Vol.112, No.3, (February 2008), pp. 608–615, ISSN 0008-543X 
Dematteo, RP. (2009). Adjuvant imatinib mesylate after resection of localised, primary 
gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled 
trial. Lancet, Vol.373, No.9669, (March 2009), pp. 1097-104, ISSN 0140-6736 
Demetri, GD. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal 
stromal tumors. New England Journal of Medicien, Vol347, No.7, (August 2002), pp. 
472-480, ISSN 0028-4793 
Demetri, GD. (2006). Efficacy and safety of sunitinib in patients with advanced 
gastrointestinal stromal tumour after failure of imatinib: a randomised controlled 
trial. Lancet, Vol.368, No.9544, (October 2006), pp. 1329-1338, ISSN 0140-6736 
Dimitrakopoulou-Strauss, A. (2007). 68 Ga-labeled bombesin studies in patients with 
gastrointestinal stromal tumors: comparison with 18F-FDG. Journal of Nuclear 
Medicine, Vol.48, No.8, (August 2007), pp. 1245-1250, ISSN 0161-5505 
Duensing, A. (2004). Protein kinase C theta (PKCtheta) expression and constitutive 
activation in gastrointestinal stromal tumors (GISTs). Cancer Research, Vol.64, 
No.15, (August 2004), pp. 5127–5131, ISSN 0008-5472 
Eisenberg, BL. (2009). Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for 
advanced primary and metastatic/recurrent operable gastrointestinal stromal 
tumor (GIST): Early results of RTOG 0132/ACRIN 6665. Journal of Surgical 
Oncology, Vol.99, No.1, (January 2009), pp. 42-47, ISSN 0022-4790 
Espinosa, I. (2008). A novel monoclonal antibody against DOG1 is a sensitive and specific 
marker for gastrointestinal stromal tumors. American Journal of Surgical Pathology, 
Vol.32, No.2, (February 2008), pp. 210–218, ISSN 0147-5185 
Essat, M. (2011). Imatinib as adjuvant therapy for gastrointestinal stromal tumors- a 
systematic review. International Journal of Cancer, Vol.128, No.9, (May 2011), pp. 
2202-2214, ISSN 0020-7136 
Fiore, M. (2009). Preoperative imatinib mesylate for unresectable or locally advanced 
primary gastrointestinal stromal tumors (GIST). European Journal of Surgical 
Oncology, Vol.35, No.7, (Ju;y 2009), pp. 739–745, ISSN 0748-7983 
Fletcher, CD. (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. 
Human Pathology, Vol.33, No.5, (May 2002), pp. 459-465, ISSN 0046-8177 
Gajiwala, KS. (2009). KIT kinase mutants show unique mechanisms of drug resistance to 
imatinib and sunitinib in gastrointestinal stromal tumor patients. Proceedings of the 
National Academy of Sciences of the United States of America, Vol.106, No.5, (February 
2009), pp. 1542–1547, ISSN 0027-8424 
Garcia dePolavieja, (2010). Gastrointestinal stromal tumours at present: An approach to 
burning questions. Clinical Translational Oncology, Vol.12, No.2, (February 2010), pp. 
100–112, ISSN 1699-048X 
Gervaz, P. (2009). Surgical management of gastrointestinal stromal tumours. British Journal 
of Surgery, Vol.96, No.6, (February 2009), pp. 567–578, ISSN 0007-1323 
www.intechopen.com
 
Treatment Options for Gastrointestinal Stromal Tumors 
 
41 
Gold, JS. (2006). Combined surgical and molecular therapy: the gastrointestinal stromal 
tumor model. Annals of Surgery, Vol.244, No.2, (August 2006), pp. 176–184, ISSN 
0003-4932 
Gold, JS. (2007). Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing 
against resistance. Annals of Surgery Oncology, Vol.14, No.4, (April 2007), pp. 1247–
1248, ISSN 1068-9265 
Gold, JS. (2009). Development and validation of a prognostic nomogram for recurrence-free 
survival after complete surgical resection of localized primary gastrointestinal 
stromal tumour: a retrospective analysis. Lancet Oncology, Vol.10, No.11, 
(November 2009), pp.1045-1052, ISSN 1470-2045 
Guo, T. (2007). Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in 
gastrointestinal stromal tumor. Clinical Cancer Research, Vol.13, No.16, (Auguet 
2007), pp. 4874-4881, ISSN 1078-0432 
Hassan, I. (2006).Clinical, pathologic, and immunohistochemical characteristics of 
gastrointestinal stromal tumors of the colon and rectum: implications for surgical 
management and adjuvant therapies. Disease of Colon and Rectum, Vol.49, No.5, 
(May 2006), pp. 609-615 ISSN 0012-3706 
Hassan, I. (2008). Surgically managed gastrointestinal stromal tumors: a comparative and 
prognostic analysis. Annals of Surgery Oncology, Vol. 15, No.1, (January 2008), pp. 
52-59, ISSN 1068-9265 
Heinrich, MC. (2005). Gastric GI stromal tumors (GISTs): the role of surgery in the era of 
targeted therapy. Journal of Surgical Oncology, Vol.90, No.3, (June 2005), pp. 195-207, 
ISSN 0022-4790 
Heinrich, MC. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal 
tumors. Journal of Clinical Oncology, Vol.24, No.29, (October 2006), pp. 4764–4774, 
ISSN 0732-183X 
Heinrich, MC. (2008). Primary and secondary kinase genotypes correlate with the biological 
and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal 
tumor. Journal of Clinical Oncology, Vol.26, No.33, (November 2008), pp. 5352-5359, 
ISSN 0732-183X 
Hirota, S. (1998). Gain-of-function mutations of c-KIT in human gastrointestinal stromal 
tumors. Science, Vol.279, No.5350, (January 1998), pp. 577-580, ISSN 0036-8075 
Horgan, S. (2011). Clinical experience with a multifunctional, flexible surgery system for 
endolumenal, single-port, and NOTES procedures. Surgical Endoscopy, Vol 25, No.2, 
(February 2011), pp. 586-592, 0930-2794 
Hou, YY. (2009). Imatinib mesylate neoadjuvant treatment for rectal malignant 
gastrointestinal stromal tumor. World Journal of Gastroenterology, Vol.15, No.15, 
(April 2009), pp. 1910-1913, ISSN 1007-9327 
Hsu, KH. (2007a). Significance of CD44 expression in gastrointestinal stromal tumors in 
relation to disease progression and survival. World Journal of Surgery, Vol.31, No.7, 
(July 2007),pp. 1438-1444, ISSN 0364-2313 
Hsu, KH. (2007b). Tumor size is a major determinant of recurrence in patients with 
resectable gastrointestinal stromal tumor. American Journal of Surgery, Vol.194, No.2, 
(August 2007), pp. 148-152, ISSN 0002-9610  
Hsu, KH. (2010a). Clinical implication and mitotic effect of CD44 cleavage in relation to 
osteopontin/CD44 interaction and dysregulated cell cycle protein in 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
42
gastrointestinal stromal tumor. Annals of Surgery Oncology, Vol.17, No.8, (August 
2010), pp. 2199-2212, ISSN 1068-9265 
Hsu, KH. (2010b). Osteopontin expression is an independent adverse prognostic factor in 
resectable gastrointestinal stromal tumor and its interaction with CD44 promotes 
tumor proliferation. Annals of Surgery Oncology, Vol.17, No.11, (November 2010), 
pp, 3043-3052, ISSN 1068-9265 
Huang, H. (2010). Different sites and prognoses of gastrointestinal stromal tumors of the 
stomach- report of 187 cases. World Journal of Surgery, Vol.34, No.7, (July 2010), pp. 
1523-1533, , ISSN 0364-2313 
Iesalnieks, I. (2005). Factors associated with disease progression in patients with 
gastrointestinal stromal tumors in the pre-imatinib era. American Journal of Clinical 
Pathology, Vol124, No.5, (November 2005), pp. 740-748, ISSN 0002-9173 
Joensuu, H. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal 
tumor. Human Pathology, Vol.39, No.10, (October 2008), pp. 1411-1419, ISSN 0046-
8177 
Joensuu, H. (2011). Vatalanib for metastatic GIST resistant to imatinib-final results of a phase 
II study. British Jornal of Cancer, Vol.104, No.11, (May 2011), pp. 1686-1690, ISSN 
0007-0920 
Karakousis, GC. (2011). Laparoscopic Versus Open Gastric Resections for Primary 
Gastrointestinal Stromal Tumors (GISTs): A Size-Matched Comparison. Annals of 
Surgical Oncology, Vol.18, No.6, (June 2011), pp. 1599-1605, ISSN 1068-9265 
Katz, D. (2004). Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. 
Anticancer Drugs, Vol.15, No.6, (July 2004), pp. 599-602, ISSN 0959-4973 
Keun, PC. (2008). Prognostic stratification of high-risk gastrointestinal stromal tumors in the 
era of targeted therapy. Annals of Surgery, Vol.247, No.6, (June 2008), pp. 1011-1018, 
ISSN 0003-4932 
Kindblom, LG. (1998). Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal 
stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. 
American Journal of Pathology, Vol.152, No.5, (May 1998), pp. 1259-1269, ISSN 0002-
9440 
Kingham, TP. (2009). Multidisciplinary treatment of gastrointestinal stromal tumors. 
Surgical Clinics of North America, Vol.243, No.6, (February 2009), pp. 217–233, ISSN 
0039-6109 
Kwon, SJ. (2001). Surgery and prognostic factors for gastric stromal tumor. World Journal of 
Surgery, Vol.25, No.3, (March 2001), pp. 290-295, ISSN 0364-2313 
Le Cesne, A. (2010). Phase II study of oral masitinib mesilate in imatinib-naïve patients with 
locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European 
Journal of Cancer, Vol.46, No.8, (May 2010), pp. 1344-1351, ISSN 0959-8049 
Lee, HE. (2008). Characteristics of KIT negative gastrointestinal stromal tumours and 
diagnostic utility of protein kinase C theta immunostaining. Journal of Clinical 
Pathology, Vol.61, No.6, (June 2008), pp. 722–729, ISSN 0021-9746 
Liegl, B. (2008). Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Journal of 
Pathology, Vol.216, No.1, (September 2008), pp. 64–74, ISSN 0022-3417 
Liegl, Bl. (2009). Monoclonal antibody DOG 1.1 shows higher sensitivity than KIT in the 
diagnosis of Gastrointestinal stromal tumors, including unusual subtypes. American 
www.intechopen.com
 
Treatment Options for Gastrointestinal Stromal Tumors 
 
43 
Journal of Surgical Pathology, Vol. 33, No.3, (March 2009), pp. 437–446, ISSN 0147-
5185 
Lo, SS. (2005). Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report 
of a case. Disease of Colon and Rectum, Vol.48, No.6, (June 2005), pp. 1316-1319, ISSN 
0012-3706 
Loughrey, MB. (2005). Gastrointestinal stromal tumour treated with neoadjuvant imatinib. 
Journal of Clinical Pathology, Vol.58, No.7, (July 2005), pp. 779–781, ISSN 0021-9746 
Machlenkin, S. (2010). The effect of neoadjuvant Imatinib therapy on rectal gastrointestinal 
stromal tumours outcome and survival. Colorectal Disease, (October 2010), doi: 
10.1111/j.1463-1318.2010.02442.x. [Epub ahead of print] 
Mandalà, M. (2007). Neoadjuvant Imatinib in a locally advanced gastrointestinal stromal 
tumour (GIST) of the rectum: a rare case of two GISTs within a family without a 
familial GIST syndrome. European Journal of Gastroenterology and Hepatology, Vol .19, 
No.8, (August 2007), pp. 711-713, ISSN 0954-691X 
Mazur, MT. (1983). Gastric stromal tumors. Reappraisal of histogenesis. American Journal of 
Surgical Pathology, Vol.7, No.4, (September 1983), pp. 507-519. ISSN 0147-5185 
Medeiros, F. (2004). KIT-negative gastrointestinal stromal tumors: proof of concept and 
therapeutic implications. American Journal of Surgical Pathology, Vol.28, No.7, (July 
2004), pp. 889–894, ISSN 0147-5185 
Miettinen, M. (2002). Pathology and diagnostic criteria of gastrointestinal stromal tumors 
(GISTs): A review. European Journal of Cancer, Vol.38, Suppl.5, (September 2002), 
pp.39-51, ISSN 0959-8049 
Miettinen, M. (2003). Gastrointestinal stromal tumors, intramural leiomyomas, and 
leiomyosarcomas in the duodenum: A clinicopathologic, immunohistochemical, 
and molecular genetic study of 167 cases. American Journal of Surgical Pathology, 
Vol.27, No.5, (May 2003), pp. 625–641, ISSN 0147-5185 
Miettinen, M. (2005). Gastrointestinal stromal tumors of the stomach: A clinicopathologic, 
immunohistochemical, and molecular genetic study of 1765 cases with long-term 
follow-up. American Journal of Surgical Pathology, Vol.29, No.1, (January 2005), pp. 
52–68, ISSN 0147-5185 
Miettinen, M. (2006). Gastrointestinal stromal tumors of the jejunum and ileum: A 
clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases 
before imatinib with long-term follow-up. American Journal of Surgical Pathology, 
Vol.30, No.4, (April 2006), pp. 477–489, ISSN 0147-5185 
Miettinen, M. (2009). DOG1 antibody in the differential diagnosis of gastrointestinal stromal 
tumors: a study of 1,840 cases. American Journal of Surgical Pathology, Vol.33, No.9, 
(September 2009), pp. 1401–1408, ISSN 0147-5185 
Nilsson, B. (2005). Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, 
and prognostication in the preimatinib mesylate era–a population-based study in 
western Sweden. Cancer, Vol.103, No.4, (February 2005), pp. 821-829, ISSN 0008-
543X 
Nishida, T. (2008). Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in 
Japan: English version. International Journal of Clinical Oncology, Vol.26, No.4, 
(February 2008), pp. 416–430, ISSN 0732-183X 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
44
Novitsky, YW. (2006). Long-term outcomes of laparoscopic resection of gastric 
gastrointestinal stromal tumors. Annals of Surgery, Vol.243, No.6, (June 2006), 
pp.:738–745, ISSN 0003-4932 
Otani, Y. (2006). Operative indications for relatively small (2–5 cm) gastrointestinal stromal 
tumor of the stomach based on analysis of 60 operated cases. Surgery, Vol.139, No.4, 
(April 2006), pp. 484–492, ISSN 0039-6060 
Parkkila, S. (2010). Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal 
tumors. Modern Pathology, Vol.23, No.5, (May 2010), pp 743-750, ISSN 0893-3952 
Patel, S. (2011). Navigating Risk Stratification Systems for the Management of Patients With 
GIST. Annals of Surgical Oncology, Vol.18, No.6, (June 2011), pp. 1698-704, ISSN 
1068-9265 
Prenen, H. (2006). Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in 
gastrointestinal stromal tumor cell lines. Pharmacology, Vol.77, No.1, (2006), pp. 11-
16, ISSN 0031-7012 
Privette, A. (2008). Laparoscopic approaches to resection of suspected gastric 
gastrointestinal stromal tumors based on tumor location. Surgical Endoscopy, Vol.22, 
No.2, (February 2008), pp. 487–494, ISSN 0930-2794 
Raut, CP. (2008). Prognostic factors for primary GIST: Prime time for personalized therapy? 
Annals of Surgery Oncology, Vol.15, No.1, (January 2008), pp. 4-6, ISSN 1068-9265 
Roberts, PJ. (2002). Clinical presentation of gastrointestinal stromal tumors and treatment of 
operable disease. European Journal of Cancer, Vol.38, Suppl.5, (September 2002), pp. 
37-38, ISSN 0959-8049 
Rossi, CR. (2003). Gastrointestinal stromal tumors: From a surgical to a molecular approach. 
International Journal of Cancer, Vol.107, No.2, (November 2003), pp. 171-176, ISSN 
0020-7136 
Rubin, BP. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. 
Cancer Research, Vol.61, No.22, (November 2001), pp. 8118-8121, ISSN 0008-5472 
Rudolph, P. (1998). Immunophenotype, proliferation, DNA-ploidy, and biological behavior 
of gastrointestinal stromal tumors: a multivariate clinicopathological study. Human 
Pathology, Vol. 29, No.8, (August 1998), pp.791-800, ISSN 0046-8177 
Rutkowski, P. (2006). Surgical treatment of patients with initially inoperable and/or 
metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib 
mesylate. Journal of Surgical Oncology, Vol.93, No.4, (March 2006), pp. 304-311, ISSN. 
0022-4790 
Sasaki, A. (2010). Tailored laparoscopic resection for suspected gastric gastrointestinal 
stromal tumors. Surgery, Vol.147, No.4, (April 2010), pp. 516-520, ISSN 0039-6060 
Sawaki, A. (2011). Phase 2 study of nilotinib as third-line therapy for patients with 
gastrointestinal stromal tumor. Cancer, (March 2011), doi: 10.1002/cncr.26120. 
[Epub ahead of print], ISSN 0008-543X 
Scarpa, M. (2008). A systematic review on the clinical diagnosis of gastrointestinal stromal 
tumors. Journal of Surgical Oncology, Vol.98. No.5, (October 2008), pp. 384–392, ISSN 
0022-4790 
Sexton, JA, (2008). Laparoscopic gastric resection for gastrointestinal stromal tumors. 
Surgical Endoscopy, Vol.22, No.12, (December 2008), pp.:2583–2587, ISSN 0930-2794 
www.intechopen.com
 
Treatment Options for Gastrointestinal Stromal Tumors 
 
45 
Shah, JN. (2005). Neoadjuvant therapy with imatinib mesylate for locally advanced GI 
stromal tumor. Gastrointestinal Endoscopy, Vol.61, No.4, (April 2005), pp. 625–627, 
ISSN 0016-5107 
Shinomura, Y. (2005). Pathophysiology, diagnosis, and treatment of gastrointestinal stromal 
tumors. Journal of Gastroenterology, Vol.40, No.8, (August 2005), pp. 775-780, ISSN 
0944-1174 
Silberhumer, GR. (2009). Surgery for gastrointestinal stromal tumors of the stomach. Journal 
of Gastrointestinal Surgery, Vol.13, No.7, (July 2009), pp. 1213–1219, ISSN 1091-255X 
Singer, S. (2002). Prognostic value of KIT mutation type, mitotic activity, and histologic 
subtype in gastrointestinal stromal tumors. Journal of Clinical Oncology, Vol.20, 
No.18, (September 2002), pp. 3898-3905, ISSN 0732-183X 
Sjölund, K. (2010). Downsizing treatment with tyrosine kinase inhibitors in patients with 
advanced gastrointestinal stromal tumors improved resectability. World Journal of 
Surgery, Vol.34, No.9, (September 2010), pp. 2090-2097, ISSN 0364-2313 stromal 
tumours. Nature, Vol.467, No.7317, (October 2010), pp. 849-853, ISSN 0028-0836 
Stroobants, S. (2003). 18FDG-Positron emission tomography for the early prediction of 
response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). 
European Journal of Cancer, Vol. 39, No. 14, (September 2003), pp. 2012-2020, ISSN 
0959-8049 
Van den Abbeele, AD. (2008). The lessons of GIST--PET and PET-CT- a new paradigm for 
imaging. The Oncologist, Vol.13m Suppl.2, (April 2008), pp. 8-13, ISSN 1083-7159 
Verweij, J. (2004). Progression-free survival in gastrointestinal stromal tumours with high-
dose imatinib: randomised trial. Lancet, Vol.364, No.9440, (October 2004), pp. 1127–
1134, ISSN 0140-6736 
West RB, Corless CL, Chen X et al (2004) The novel marker, DOG1, is expressed 
ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA 
mutation status. Am J Pathol 165(1):107–113 
West, RB. (2004). The novel marker, DOG1, is expressed ubiquitously in gastrointestinal 
stromal tumors irrespective of KIT or PDGFRA mutation status. American Journal of 
Pathology, Vol.165, No.1, (July 2004), pp. 107-113, ISSN 0002-9440 
Winer, JH. (2011). Management of recurrent gastrointestinal stromal tumors. Journal of 
Surgical Oncology, (February 2011), doi: 10.1002/jso.21890. [Epub ahead of print], 
ISSN 0022-4790 
Woodall, CE, 3rd. (2009). An evaluation of 2537 gastrointestinal stromal tumors for a 
proposed clinical staging system. Archives of Surgery, Vol.144, No.7, (July 2009), pp. 
670-678, ISSN 0004-0010 
Yan, H. (2003). Prognostic assessment of gastrointestinal stromal tumor. American Journal of 
Clinical Oncology, Vol.26, No.3, (June 2003), pp. 221-228, ISSN 0277-3732 
Yang, WL. (2009). Duodenal gastrointestinal stromal tumor: Clinical, pathologic, 
immunohistochemical characteristics, and surgical prognosis. Journal of Surgical 
Oncology, Vol.100, No.7, (December 2009), pp. 606–610, ISSN 0022-4790 
Yoon, SS. (2007). Should surgical resection be combined with imatinib therapy for locally 
advanced or metastatic gastrointestinal stromal tumors? Annals of Surgery Oncology, 
Vol.14, No.6, (June 2007), pp. 1784-1786, ISSN 1068-9265 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
46
Zhu, J. (2010). A long-term follow-up of the imatinib mesylate treatment for the patients 
with recurrent GIST- the liver metastasis and the outcome.BMC cancer, Vol.13, 
No.10, (May 2010), pp. 199, ISSN 1471-2407 
www.intechopen.com
Gastrointestinal Stromal Tumor
Edited by Prof. Raimundas Lunevicius
ISBN 978-953-51-0580-0
Hard cover, 120 pages
Publisher InTech
Published online 27, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Almost 30 years have gone by since the postulation that GISTs derive from mesenchymal stem elements, and
only 15 years have gone by since the definitive detection of origin of GISTs. Research in the last decade was
more focused upon the justification of imatinib mezylate therapy in GISTs and clarification why a secondary
resistance that occurred during the kinase inhibitors therapy. The era of therapy for GISTs, targeting the
primary activating mutations in the KIT proto-oncogene; is being proclaimed as bringing the message of
special importance to the pathologist role in multidisciplinary team that are responsible for treating patients
with locally advanced or metastatic GIST. This is the first conclusive message forthcoming from this book. On
the other hand, the book provides summarised and case-based knowledge on current management of
gastrointestinal and extragastrointestinal stromal tumours. We hope that this book may be considered as a
worthwhile timely addition to clinical science dissemination, medical education, further basic and clinical
research.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Kai-Hsi Hsu (2012). Treatment Options for Gastrointestinal Stromal Tumors, Gastrointestinal Stromal Tumor,
Prof. Raimundas Lunevicius (Ed.), ISBN: 978-953-51-0580-0, InTech, Available from:
http://www.intechopen.com/books/gastrointestinal-stromal-tumor/treatment-options-for-gastrointestinal-
stromal-tumors
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
